Morepen Laboratories Limited submitted its Q2 & H1 FY27 investor presentation to the National Stock Exchange of India Ltd. and BSE Limited. The presentation highlights the company's second consecutive quarter of record revenue and earnings, marking a significant transformation in its earnings profile.

Financial Performance Highlights

  • H1 Export Revenue: ₹654 Crore, up 122% YoY
  • Q1 Export Growth: 111% YoY
  • Q2 Export Growth: 131% YoY
  • Export Share of Sales Revenue: ~50% (vs 35% in H1 FY26)
  • Domestic Revenue Growth: +22% YoY
  • Medical Devices Q2 Revenue: ₹208 Crore, +65% YoY
  • Medical Devices H1 Revenue: ₹399 Crore, +39% YoY

CDMO Business Performance

  • CDMO commercial supplies scaled up materially in Q2 FY27
  • CDMO now represents over 52% of combined API + CDMO revenue
  • H1 CDMO Revenue: ₹825 Crore (mentioned in context of scale)

API Business Performance

  • API exports to over 90 countries
  • ~76% of API revenue from exports
  • New molecules now represent 25% of API revenue (vs 14% in H1 FY26)
  • New molecules showed +50% YoY growth in H1 FY27

Capacity and Expansion

  • Current manufacturing capacity: 614 KL
  • Commissioned ahead of schedule
  • Expanding to 800 KL with further expansion behind visibility
  • Global CDMO Mandate received in February 2026

Medical Devices Business

  • Leadership in Glucose + BP Monitoring
  • Installed base of ~20 million meters
  • Consumables: ~500 million strips per annum
  • All-India distribution + service network
  • Backward-integrated manufacturing
  • Operating leverage improving as scale grows

Business Mix Transformation

  • Revenue mix becoming more global with 50% export share
  • Higher-value business mix with longer-duration programmes
  • Better capital efficiency and improved working capital
  • Higher operating leverage leading to stronger earnings profile

Strategic Positioning

  • Established chemistry platform evolving into innovation-led manufacturing
  • Innovation Hub developing new technologies
  • Regulatory credentials include USFDA/ANDA/global approvals
  • ESG initiatives including ZLD (Zero Liquid Discharge) and solar power
  • Diversified, compliant and scalable platform for long-term growth

Forward-Looking Statements

The presentation contains forward-looking statements regarding business strategy, growth plans, manufacturing expansion, regulatory developments, market opportunities, future financial performance, operating leverage, and industry outlook. These statements are subject to various risks and uncertainties including market conditions, regulatory environment, customer demand, competitive intensity, pricing pressures, supply chain dynamics, currency fluctuations, and technological changes.